🔓
Sign in as a Member to unlock the full view of S.1774. · Full carveout list, all affected companies, party defectors, and 30-day trade predictions.
Become a Member$29.99/mo already a Member? Sign in →
S.1774 · 119TH CONGRESS

Protecting Minors in Federal Health Plans Act

Status
In Committee
Sponsor
Risch, James E. (R-Idaho)
Official Source
Investability
0/100
Stage
COMMITTEE
Related Bills
0
Full Text
4,315 chars
Alive
Yes

What This Bill Does · Plain English

Summary
Plain-English summary not yet available for this bill. Check back after our next analysis run.

Action Timeline

2025-05-15
Introduced in Senate
2025-05-15
Read twice and referred to the Committee on Homeland Security and Governmental Affairs.

Frequently Asked Questions

Did S.1774 pass?
S.1774 is still alive. Current stage: COMMITTEE. Pass likelihood: pending.
Who sponsored S.1774?
S.1774 was sponsored by James E. Risch (R-Idaho).

Full Bill Text

119 S1774 IS: Protecting Minors in Federal Health Plans Act U.S. Senate 2025-05-15 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. II 119th CONGRESS 1st Session S. 1774 IN THE SENATE OF THE UNITED STATES May 15, 2025 Mr. Risch (for himself, Ms. Lummis , Mr. Ricketts , and Mr. Cramer ) introduced the following bill; which was read twice and referred to the Committee on Homeland Security and Governmental Affairs A BILL To amend title 5, United States Code, to provide that certain treatments may not be covered under the health insurance program carried out under chapter 89 of that title, and for other purposes. 1. Short title This Act may be cited as the Protecting Minors in Federal Health Plans Act . 2. Prohibitions on FEHB coverage for certain treatment (a) In general Section 8902 of title 5, United States Code, is amended by adding at the end the following: (q) (1) In this subsection, the term gender-affirming care or service — (A) means a medical intervention designed to treat gender dysphoria; (B) includes hormone therapy, the use of puberty blockers, and any surgical procedure aimed at gender transition; and (C) notwithstanding subparagraphs (A) and (B), does not include— (i) a service provided to an individual with a medically verifiable disorder of sexual development, including an individual with an irresolvable and ambiguous external sex characteristic, including an individual born with— (I) 46 XY chromosomes and under-virilization; (II) 46 XX chromosomes and virilization; or (III) both ovarian and testicular tissue; (ii) a service provided to treat a disorder diagnosed by a physician in which the physician has determined through genetic or biochemical testing that the applicable individual has abnormal (or otherwise inconsistent with typical male or female characteristics)— (I) sex chromosome structure; (II) sex steroid hormone production; or (III) sex steroid hormone action; (iii) the treatment of any infection, injury, disease, or disorder that has been caused or worsened by a medical intervention described in subparagraph (A), without regard to whether that intervention— (I) was performed in compliance with State or Federal law; or (II) was covered under a contract under this chapter, as of the date on which the intervention was performed; (iv) any procedure that— (I) is performed to address a physical disorder, injury, or illness that, as certified by a physician, poses an imminent risk of death or impairment of major bodily function; and (II) is not performed for the purpose of gender transition or to alleviate psychological, physical, or mental distress relating to gender; (v) a prescription for puberty suppression or blocking that is used to normalize puberty in an individual younger than 18 years of age who has been diagnosed with precocious puberty; (vi) any hormone therapy procedure that is used to stimulate puberty in an individual younger than 18 years of age who has been diagnosed with delayed puberty, if the hormones administered through that procedure are— (I) consistent with the biological sex of the individual; and (II) used to stimulate a normal puberty consistent with the biological sex of the individual; or (vii) male circumcision. (2) Subject to paragraph (3), and notwithstanding any other provision of law or regulation, a contract under this chapter may not include coverage for any gender-affirming care or service for any individual younger than 18 years of age. (3) In the case of an individual who, as of the effective date of this subsection, is younger than 18 years of age and who, as of that effective date, is undergoing hormone therapy that, as of the day before that effective date, is covered by a contract under this chapter, that hormone therapy may continue to be covered under such a contract after that effective date if the hormone therapy is provided pursuant to a reduction schedule that— (A) is supervised by a physician; and (B) requires that therapy to conclude not later than 1 year after that effective date. . (b) Applicability The amendment made by subsection (a) shall apply with respect to any contract entered into, or renewed for a contract year, on or after the date of enactment of this Act.
🔒 GovGreed Pro · Trading Intelligence on S.1774 Get Access — $29.99/mo
Loading intelligence layer…
Bill text sourced from GovInfo.gov · public domain · last updated 2026-11-17. Plain-English summary, score breakdown, and trading-intelligence panels are GovGreed-original analysis derived from STOCK Act filings, SEC Form 4 disclosures, FEC contributions, and Senate LDA lobbying reports — all publicly filed federal records. GovGreed is not affiliated with the U.S. Government. Not financial advice. [live render]